•
Dec 31, 2020

Anika Q4 2020 Earnings Report

Anika's Q4 2020 financial results were reported.

Key Takeaways

Anika Therapeutics reported a 10% year-over-year revenue increase for Q4 2020, contributing to a 14% revenue increase for the full year. The company successfully integrated Parcus Medical and Arthrosurface acquisitions, diversifying its portfolio and business.

Anika ended the year with double-digit revenue growth.

The company had positive operating cash flow.

Anika integrated Parcus Medical and Arthrosurface acquisitions.

The company is focused on 2024 targets of doubling revenues and expanding profitability.

Total Revenue
$32.7M
Previous year: $29.8M
+9.8%
EPS
$0.12
Previous year: $0.43
-72.1%
Gross Profit
$16.7M
Previous year: $21.1M
-20.7%
Cash and Equivalents
$95.8M
0
Free Cash Flow
$2.14M
Previous year: $12.8M
-83.2%
Total Assets
$366M
Previous year: $331M
+10.6%

Anika

Anika

Forward Guidance

Due to the continued uncertainty in the global market associated with the impact of the COVID-19 pandemic, the company is not providing detailed financial guidance for 2021 at this time.